Eribulin + Cyclophosphamide + Docetaxel
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2 Negative Breast Cancer
Conditions
HER2 Negative Breast Cancer
Trial Timeline
Jun 1, 2012 → Jul 1, 2016
NCT ID
NCT01527487About Eribulin + Cyclophosphamide + Docetaxel
Eribulin + Cyclophosphamide + Docetaxel is a phase 2 stage product being developed by Eisai for HER2 Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01527487. Target conditions include HER2 Negative Breast Cancer.
What happened to similar drugs?
2 of 20 similar drugs in HER2 Negative Breast Cancer were approved
Approved (2) Terminated (1) Active (17)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01527487 | Phase 2 | Completed |
Competing Products
20 competing products in HER2 Negative Breast Cancer